PT-141 Dosage: Doses Studied, Units and Chart
What doses of PT-141 have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 9 studies
- with a stated dose, listed below
- Frequency
- Varies by study
- as used in studies
- Half-life
- approximately 2.7 hours (range 1.9-4.0 h)
- subcutaneous, in people · FDA label (Vyleesi)
- Vial sizes sold
- 10 mg
Dosing on the FDA label
Quoted from the approved product label. It applies to the approved product used as prescribed, not to compounded or research-chemical versions.
- 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated sexual activity · FDA label (Vyleesi)
- Not more than one dose within 24 hours; no more than 8 doses per month · FDA label (Vyleesi)
- Dose cap per month · FDA label (Vyleesi)
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| 1.75 mg | as needed before sexual activity · subcutaneous · 24 weeks | Human RCTn = 1202 | Journal of women's health 2022, PMID 35230162 |
| 1.75 mg | as needed · subcutaneous · 24 weeks | Human RCTn = 1267 | Obstetrics and gynecology 2019, PMID 31599840 |
| 1.75 mg | subcutaneous | Human RCT | The journal of sexual medicine 2019, PMID 31277966 |
| 0.75, 1.25 and 1.75 mg | subcutaneous | Human RCTn = 397 | Journal of hypertension 2017, PMID 27977473 |
| 20 mg | single doses on days 1, 4 and 7, with or without ethanol · intranasal | Human RCTn = 24 | Clinical therapeutics 2017, PMID 28189361 |
| 0.75, 1.25 or 1.75 mg | as desired · subcutaneous · 12 weeks | Human RCTn = 327 | Women's health 2016, PMID 27181790 |
| 10 mg | 45 minutes to 2 hours before sexual stimulation, at least 16 doses/attempts · intranasal | Human RCTn = 342 | The Journal of urology 2008, PMID 18206919 |
| 20 mg | single dose · intranasal | Human RCTn = 18 | The journal of sexual medicine 2006, PMID 16839319 |
| 0.3 to 10 mg healthy; 4 or 6 mg in ED patients | subcutaneous | Human RCT | International journal of impotence research 2004, PMID 14999221 |
Dose to syringe units
For a 10 mg vial mixed with 2 mL of bacteriostatic water (5 mg/mL), on a U-100 syringe. These are reference amounts for the math, not suggested doses.
- 0.25 mg
- 5 u
- 0.5 mg
- 10 u
- 1 mg
- 20 u
- 1.5 mg
- 30 u
- 2 mg
- 40 u
- 2.5 mg
- 50 u
Before anyone considers it
- PT-141 is FDA approved for HSDD (Vyleesi); research-chemical versions are not the approved drug.
- Compounded and research-chemical versions are not the approved product and are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
What the Vyleesi label specifies
The Vyleesi label gives 1.75 mg subcutaneously, in the abdomen or thigh, as needed at least 45 minutes before anticipated sexual activity.[3]
The label also bars repeat dosing within 24 hours and says more than 8 doses per month is not recommended.[3]
The label states that the duration of efficacy after each dose is unknown and the optimal window has not been fully characterized.[3]
PT-141 dosage chart: the labelled dose in mg, mL and units
The one labelled presentation is a single-dose autoinjector holding 1.75 mg in 0.3 mL of clear solution.[3]
1.75 mg in 0.3 mL is 5.83 mg/mL, and 0.3 mL (0.3 cc) is 30 units on a U-100 scale. The autoinjector is not drawn up with a syringe, so the units figure only helps translate the volume.
Calculated from dose mg 1.75; volume mL 0.3; units per mL 100. Formula: 1.75 / 0.3 = 5.83 mg/mL; 0.3 mL x 100 = 30 units
The label tells prescribers to stop treatment after 8 weeks when the patient reports no improvement in her symptoms.[3]
How dose was chosen in the trials
The phase 2 dose-finding trial in premenopausal women compared 0.75, 1.25 and 1.75 mg self-administered as desired over 12 weeks.[9]
The efficacy comparison pooled the 1.25 and 1.75 mg arms against placebo: +0.7 versus +0.2 satisfying sexual events per month (p = 0.0180).[9]
Both RECONNECT phase 3 trials then fixed the amount at 1.75 mg subcutaneously as needed, for 24 weeks of treatment.[5]
Studies in men used other routes and amounts
In men with erectile dysfunction who did not respond to sildenafil, an intranasal spray of 10 mg was used 45 minutes to 2 hours before sexual stimulation; this route is not on the Vyleesi label.[10]
A subcutaneous trial in men with erectile dysfunction used 4 or 6 mg PT-141 or placebo in a crossover design, in the presence of visual sexual stimulation.[12]
The intranasal authors wrote that further studies with different dosages and treatment regimens were necessary.[10]
Common questions
How many units is 1 mg of PT-141?
It depends on the water added. A 10 mg vial with 2 mL of water gives 5 mg/mL, so 1 mg is 20 units on a U-100 syringe. Use the calculator for other mixes.
Is PT-141 FDA approved?
PT-141 is FDA approved for HSDD (Vyleesi). Products sold as research chemicals are not the approved drug and are not checked by the FDA.
What is the PT-141 dosage for women?
The Vyleesi label gives 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated sexual activity.[3]
What is the PT-141 dosage for men?
The Vyleesi label states it is not indicated for HSDD in postmenopausal women or in men, so no labelled dose exists for men. The male trials above used other routes and amounts.[3]
How often can PT-141 be used?
The label bars repeat dosing within 24 hours and does not recommend more than 8 doses per month.[3]
Does PT-141 work orally?
The label gives its bioavailability figure for the subcutaneous route, about 100%, and describes an injection product only; it states no figure for swallowed bremelanotide.[3]
How many 1.75 mg doses are in a 10 mg PT-141 vial?
10 mg divided by 1.75 mg gives 5 whole doses with 1.25 mg left over. With 1, 2 or 3 mL of water each 1.75 mg dose is 17.5, 35 or 52.5 units. This is arithmetic on the labelled dose, not a statement that a 10 mg vial is a labelled product.
Calculated from vial mg 10; dose mg 1.75; water mL 1, 2, 3; units per mL 100. Formula: doses = floor(10 / 1.75) = 5; leftover = 10 - 5 x 1.75 = 1.25 mg; units = 1.75 x mL / 10 x 100
More on PT-141
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3These highlights do not include all the information needed to use VYLEESI ® safely and effectively. See full prescribing information for VYLEESI VYLEESI (bremelanotide injection), for subcutaneous use Initial U.S. Approval: 2019FDA label (Vyleesi), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 4Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022PMID 35230162Accessed 2 Oct 2026
- 5Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstetrics and gynecology · 2019PMID 31599840Accessed 2 Oct 2026
- 6Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.The journal of sexual medicine · 2019PMID 31277966Accessed 2 Oct 2026
- 7Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.Journal of hypertension · 2017PMID 27977473Accessed 2 Oct 2026
- 8Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.Clinical therapeutics · 2017PMID 28189361Accessed 2 Oct 2026
- 9Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.Women's health (London, England) · 2016PMID 27181790Accessed 2 Oct 2026
- 10Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.The Journal of urology · 2008PMID 18206919Accessed 2 Oct 2026
- 11An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.The journal of sexual medicine · 2006PMID 16839319Accessed 2 Oct 2026
- 12Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.International journal of impotence research · 2004PMID 14999221Accessed 2 Oct 2026
Found an error? Report a correction.